12:00 AM
 | 
Jun 05, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ReoPro abciximab: Marketed

Preliminary 6-month data from Centocor's Phase II ADMIRAL trial of 300 French patients with acute myocardial infarction (AMI) undergoing angioplasty and stent placement showed that 11 of 149 patients (7.3 percent) receiving ReoPro experienced the primary end point of death, nonfatal reinfarction or urgent target vessel revascularization...

Read the full 212 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >